Principal Investigator
Terrence Bradley
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240363
Clinical Trial Summary
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination with Ruxolitinib in Participants With Myeloproliferative Neoplasms
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Leukemia/heme
Contact Information
Phone Number
305-243-2647